According to the China Medical Insurance report, a few days ago, the State Medical Insurance Bureau released the list of products applied for through formal inspection in the catalogue of national basic medical insurance, occupational insurance and maternity insurance in 2022. A total of 343 products have officially passed the formal inspection. The total number of Western medicine and Chinese medicine outside the catalogue is 198, and the total number of western medicine and Chinese medicine in the catalogue is 145.

Among the 343 products that have officially passed the formal inspection It includes the first national COVID-19 oral oral alivudine from Henan authentic biotechnology research and development, COVID-19 from Ruirui oral megatron tablets / ritona tablets, 02126.HK CAR-T product Rigelin injection, "influenza shengshen" rosiglitazone blend and spinal muscular dystrophy (SMA) drug oral solution, and many other rare diseases.

According to the State Medical Insurance Bureau, the catalogue of medical insurance products is divided into enterprise application, form inspection, expert review, evaluation evaluation, and so on, and formal inspection is only one of them. Through the formal inspection, it is shown that the quality products are qualified to enter the next step of the expert training environment. Only all the environments that pass through the directory can be most included in the national medical insurance catalogue.

In the next step, the State Medical Insurance Bureau will organize expert training in accordance with the requirements of the Law on the Administration of basic Medical Insurance and the 2022 National catalogue of basic Medical Insurance, Occupational Insurance and Maternity Insurance. If progress is successful, a new version of the catalogue of medical insurance products will be published in November and will be implemented on January 1 next year.